Applying Decentralized Trial Strategies to Dementia Research Programs

Dementia trials face unique recruitment and retention challenges: anxiety-inducing site visits for patients with cognitive decline, caregiver burden from frequent travel, geographic limitations excluding qualified participants. Traditional trial models significantly underrepresent the aging population that will ultimately use these therapies. How can sponsors expand access while maintaining data quality and regulatory compliance?

Dr. David Miller, Clinical Vice President and former Chair of the Alzheimer's Association Research Roundtable, shares practical approaches for integrating decentralized clinical trial (DCT) methods into dementia studies. Drawing from real-world implementation experience, including large-scale dementia trial migrations during COVID-19, this presentation addresses critical considerations for remote assessment validity, measurement consistency, and technology appropriateness for older adults.

Key topics explored:

• Strategies for migrating clinician-rated assessments from site-based to home-based administration
• Balancing technology solutions with essential human touchpoints for geriatric populations
• Maintaining data quality and measurement accuracy when moving assessments remotely
• Practical approaches to reducing patient and caregiver burden while preserving endpoint reliability

Watch below to gain essential guidance for designing patient-centric dementia trials that improve diversity, retention, and participant experience.